Centessa Pharmaceuticals (CNTA) Amortization of Deferred Charges (2025 - 2026)
Centessa Pharmaceuticals (CNTA) reported Amortization of Deferred Charges of $345000.0 for Q1 2026, up 10.58% year-over-year from $312000.0 in Q1 2025, and up 23.66% on a QoQ basis from $279000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 2 years of Amortization of Deferred Charges data on file, last reported at $345000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 10.58% year-over-year to $345000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 280.77% YoY) and the FY2025 annual result came in at $1.2 million, changed N/A from the prior year.
- Amortization of Deferred Charges grew to $345000.0 in Q1 2026 per CNTA's latest filing, from $279000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $345000.0 in Q1 2026 and bottomed at $271000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 345,000.00 |
| Mar 31, 2026 | 345,000.00 |
| Dec 31, 2025 | 279,000.00 |
| Dec 31, 2025 | 279,000.00 |
| Sep 30, 2025 | 271,000.00 |
| Sep 30, 2025 | 271,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 312,000.00 |
| Mar 31, 2025 | 312,000.00 |